What does KPV cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [4] |
| Compounded pharmacy | Not published | No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient KPV under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for topical or oral use only, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7] |
What is the list price of KPV?
There is no list price: KPV is not an FDA approved drug. Products sold as dietary supplements or research chemicals are not lawful for human drug use and are not a comparable price.
Does insurance cover KPV?
Not covered by commercial plans or Medicare because it is an unapproved compounded product.
What changes the price?
- HHS's October 2026 draft policy covers only single-ingredient compounding under conditions (patient-specific prescription, allowed route, tested substance from an FDA-registered manufacturer); blends are excluded and no qualifying pharmacy price has been verified yet
Frequently asked questions
How much does KPV cost without insurance?
No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient KPV under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for topical or oral use only, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7]
Does insurance cover KPV?
Not covered by commercial plans or Medicare because it is an unapproved compounded product. [4]
What is the list price of KPV?
There is no list price: KPV is not an FDA approved drug. Products sold as dietary supplements or research chemicals are not lawful for human drug use and are not a comparable price.
Related pages
- KPV: evidence, legality, and access
- BPC-157 vs KPV (BPC-157 cost)
- KPV vs LL-37
- Inflammation and inflammatory bowel disease: peptide evidence
- Inflammatory bowel disease (Crohn disease and ulcerative colitis): peptide evidence
- Autoimmune disease: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
Sources
- [1]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [4]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [6]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS notice of availability of a draft policy, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy; publication scheduled October 30, 2026)Federal Register, 2026
- [7]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026